{"id":8971,"date":"2017-04-24T12:12:54","date_gmt":"2017-04-24T16:12:54","guid":{"rendered":"https:\/\/research.ncsu.edu\/otcnv\/?p=8971"},"modified":"2023-11-20T20:53:54","modified_gmt":"2023-11-21T01:53:54","slug":"biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer","status":"publish","type":"post","link":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/","title":{"rendered":"Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer"},"content":{"rendered":"\n\n\n\n\n<p class=\"wp-block-paragraph\">North Carolina based Biomarck Pharmaceuticals, Inc. has received FDA allowance l to begin human trials for their patented compound BIO-11006, for adults with lung cancer.&nbsp; Discovered by Dr. <span class=\"xn-person\">Ken Adler<\/span> at <span class=\"xn-org\">North Carolina State University<\/span> working in partnership with Biomarck, inhaled Bio-11006 has demonstrated effectiveness on human cell cultures and animals in the laboratory. It demonstrated impressive results in adult tumors and childhood cancers, specifically, Rhabdomyosarcoma, Neuroblastoma and Osteosarcoma in children. BIO-11006 has shown to be safe and tolerable in over 200 adult humans that have received the drug in previous studies for lung diseases.<\/p>\n\n\n<div class=\"wp-block-ncst-buttons\"><div class=\"wp-block-ncst-button\"><a href=\"https:\/\/www.prnewswire.com\/news-releases\/fda-allows-novel-inhaled-treatment-bio-11006-to-commence-human-trials-in-adults-with-lung-cancer-300443319.html\" class=\"btn ncst-block__button-link\" data-ncst-lightbox=\"false\" data-ua-cat=\"Button Block\" data-ua-action=\"Button Click\" data-ua-label=\"https:\/\/www.prnewswire.com\/news-releases\/fda-allows-novel-inhaled-treatment-bio-11006-to-commence-human-trials-in-adults-with-lung-cancer-300443319.html\"><span class=\"text\">Read More<\/span><span class=\"arrow-indicator\"><svg \n\tclass=\"wolficon wolficon-arrow-right-bold\"\n\trole=\"img\"\n\taria-hidden=\"1\">\n\t\t<use xlink:href=\"#wolficon-arrow-right-bold\"><\/use>\n<\/svg>\n<\/span><\/a><\/div>\n\n<\/div>\n\n","protected":false,"raw":"<!-- wp:ncst\/dynamic-header {\"block\":\"ncst\/default-post-header\"} -->\n<!-- wp:ncst\/default-post-header {\"caption\":\"\",\"showAuthor\":false,\"showReadingTime\":false} \/-->\n<!-- \/wp:ncst\/dynamic-header -->\n\n<!-- wp:paragraph -->\n<p>North Carolina based Biomarck Pharmaceuticals, Inc. has received FDA allowance l to begin human trials for their patented compound BIO-11006, for adults with lung cancer.&nbsp; Discovered by Dr. <span class=\"xn-person\">Ken Adler<\/span> at <span class=\"xn-org\">North Carolina State University<\/span> working in partnership with Biomarck, inhaled Bio-11006 has demonstrated effectiveness on human cell cultures and animals in the laboratory. It demonstrated impressive results in adult tumors and childhood cancers, specifically, Rhabdomyosarcoma, Neuroblastoma and Osteosarcoma in children. BIO-11006 has shown to be safe and tolerable in over 200 adult humans that have received the drug in previous studies for lung diseases.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:ncst\/buttons -->\n<div class=\"wp-block-ncst-buttons\"><!-- wp:ncst\/button -->\n<div class=\"wp-block-ncst-button\"><a href=\"https:\/\/www.prnewswire.com\/news-releases\/fda-allows-novel-inhaled-treatment-bio-11006-to-commence-human-trials-in-adults-with-lung-cancer-300443319.html\" class=\"btn ncst-block__button-link\" data-ncst-lightbox=\"false\" data-ua-cat=\"Button Block\" data-ua-action=\"Button Click\" data-ua-label=\"https:\/\/www.prnewswire.com\/news-releases\/fda-allows-novel-inhaled-treatment-bio-11006-to-commence-human-trials-in-adults-with-lung-cancer-300443319.html\"><span class=\"text\">Read More<\/span><span class=\"arrow-indicator\"><!-- wp:ncst\/wolficon {\"slug\":\"arrow-right-bold\"} -->\n<svg class=\"wp-block-ncst-wolficon wolficon\" role=\"img\" aria-hidden=\"true\"><use xlink:href=\"#wolficon-arrow-right-bold\"\/><\/svg>\n<!-- \/wp:ncst\/wolficon --><\/span><\/a><\/div>\n<!-- \/wp:ncst\/button --><\/div>\n<!-- \/wp:ncst\/buttons -->"},"excerpt":{"rendered":"<p>North Carolina based Biomarck Pharmaceuticals, Inc. has received FDA allowance l to begin human trials for their patented compound BIO-11006, for adults with lung cancer.&nbsp; Discovered by Dr. Ken Adler&hellip;<\/p>\n","protected":false},"author":239,"featured_media":12304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"source":"","ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":false,\"showDate\":true,\"showFeaturedVideo\":false,\"caption\":\"\",\"showReadingTime\":false}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[2,3],"tags":[31,40,161],"_ncst_magazine_issue":[],"class_list":["post-8971","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-startup-news","tag-biomarck","tag-cancer","tag-pharmaceuticals"],"displayCategory":null,"acf":{"ncst_posts_meta_modified_date":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer - Office of Research Commercialization<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer - Office of Research Commercialization\" \/>\n<meta property=\"og:description\" content=\"North Carolina based Biomarck Pharmaceuticals, Inc. has received FDA allowance l to begin human trials for their patented compound BIO-11006, for adults with lung cancer.&nbsp; Discovered by Dr. Ken Adler&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Office of Research Commercialization\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-24T16:12:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-21T01:53:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sasha Campbell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sasha Campbell\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/\"},\"author\":{\"name\":\"Sasha Campbell\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"headline\":\"Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer\",\"datePublished\":\"2017-04-24T16:12:54+00:00\",\"dateModified\":\"2023-11-21T01:53:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/\"},\"wordCount\":114,\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"keywords\":[\"Biomarck\",\"cancer\",\"pharmaceuticals\"],\"articleSection\":[\"News\",\"Startup News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/\",\"name\":\"Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer - Office of Research Commercialization\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"datePublished\":\"2017-04-24T16:12:54+00:00\",\"dateModified\":\"2023-11-21T01:53:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"contentUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"width\":300,\"height\":300,\"caption\":\"The logo features a blue and green diamond-shaped interlocking icon next to the stacked text \\\"Biomarck Pharmaceuticals.\\\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/04\\\/24\\\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\",\"name\":\"Office of Research Commercialization\",\"description\":\"Just another Research and Innovation site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\",\"name\":\"Sasha Campbell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"caption\":\"Sasha Campbell\"},\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/author\\\/sasha-campbell\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer - Office of Research Commercialization","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer - Office of Research Commercialization","og_description":"North Carolina based Biomarck Pharmaceuticals, Inc. has received FDA allowance l to begin human trials for their patented compound BIO-11006, for adults with lung cancer.&nbsp; Discovered by Dr. Ken Adler&hellip;","og_url":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/","og_site_name":"Office of Research Commercialization","article_published_time":"2017-04-24T16:12:54+00:00","article_modified_time":"2023-11-21T01:53:54+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","type":"image\/png"}],"author":"Sasha Campbell","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sasha Campbell"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/"},"author":{"name":"Sasha Campbell","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"headline":"Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer","datePublished":"2017-04-24T16:12:54+00:00","dateModified":"2023-11-21T01:53:54+00:00","mainEntityOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/"},"wordCount":114,"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","keywords":["Biomarck","cancer","pharmaceuticals"],"articleSection":["News","Startup News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/","url":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/","name":"Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer - Office of Research Commercialization","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#website"},"primaryImageOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","datePublished":"2017-04-24T16:12:54+00:00","dateModified":"2023-11-21T01:53:54+00:00","author":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"breadcrumb":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/#primaryimage","url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","contentUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","width":300,"height":300,"caption":"The logo features a blue and green diamond-shaped interlocking icon next to the stacked text \"Biomarck Pharmaceuticals.\""},{"@type":"BreadcrumbList","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/04\/24\/biomarck-pharmaceuticals-gain-fda-allowance-to-begin-human-trials-for-inhaled-treatment-for-adults-with-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/research.ncsu.edu\/commercialization\/"},{"@type":"ListItem","position":2,"name":"Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/research.ncsu.edu\/commercialization\/#website","url":"https:\/\/research.ncsu.edu\/commercialization\/","name":"Office of Research Commercialization","description":"Just another Research and Innovation site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/research.ncsu.edu\/commercialization\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8","name":"Sasha Campbell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","caption":"Sasha Campbell"},"url":"https:\/\/research.ncsu.edu\/commercialization\/author\/sasha-campbell\/"}]}},"_links":{"self":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/8971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/users\/239"}],"replies":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/comments?post=8971"}],"version-history":[{"count":2,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/8971\/revisions"}],"predecessor-version":[{"id":15202,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/8971\/revisions\/15202"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media\/12304"}],"wp:attachment":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media?parent=8971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/categories?post=8971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/tags?post=8971"},{"taxonomy":"_ncst_magazine_issue","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/_ncst_magazine_issue?post=8971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}